Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
2.
Neth J Med ; 75(3): 127, 2017 Apr.
Article in English | MEDLINE | ID: mdl-28469055
4.
Clin Infect Dis ; 53(9): 860-9, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21914851

ABSTRACT

BACKGROUND: Clostridium difficile infection (CDI) due to polymerase chain reaction (PCR) ribotype 027 (type 027) has been described worldwide. In some countries, an increase was reported of toxin A-negative PCR ribotype 017 (type 017). We encountered an outbreak due to these 2 types occurring simultaneously in a 980-bed teaching hospital in the Netherlands. METHODS: In a case-control study from May 2005 through January 2007, we investigated general and type-specific risk factors as well as outcome parameters for CDI due to type 027 or 017. Clonal dissemination was investigated by multilocus variable number of tandem repeat analysis (MLVA). RESULTS: We identified 168 CDI patients: 57 (34%) with type 017, 46 (27%) with type 027, and 65 (39%) with 1 of 36 different other types. As controls, we included 77 non-CDI diarrheal patients and 162 patients without diarrhea. Risk factors for CDI were nasogastric intubation, recent hospitalization, and use of cephalosporins and clindamycin. Type-specific risk factors were older age for both types 017 and 027, use of clindamycin and immunosuppressive agents for type 017, and use of fluoroquinolones for type 027. At day 30 of follow-up, the overall mortality among patients with types 017, 027, other types, non-CDI diarrheal patients, and nondiarrheal patients was 23%, 26%, 3%, 2%, and 6%, respectively. MLVA showed persistent clonal dissemination of types 017 and 027, despite appropriate infection control measures. CONCLUSIONS: Patients with CDI have type-specific risk factors and mortality rates, with prolonged clonal spread of type 027 or 017.


Subject(s)
Clostridioides difficile/classification , Clostridioides difficile/isolation & purification , Clostridium Infections/epidemiology , Cross Infection/epidemiology , Disease Outbreaks , Adolescent , Adult , Aged , Aged, 80 and over , Case-Control Studies , Clostridioides difficile/genetics , Clostridioides difficile/pathogenicity , Clostridium Infections/microbiology , Clostridium Infections/mortality , Cross Infection/microbiology , Cross Infection/mortality , Female , Hospitals , Humans , Male , Middle Aged , Netherlands , Ribotyping/methods , Risk Factors , Treatment Outcome , Young Adult
6.
J Thromb Haemost ; 9(1): 79-84, 2011 Jan.
Article in English | MEDLINE | ID: mdl-20946181

ABSTRACT

BACKGROUND: Patients with a first episode of idiopathic venous thromboembolism (IVTE) have an estimated 10% incidence of cancer within 12 months after diagnosis. However, the utility of screening for cancer in this population is controversial. METHODS: In this prospective concurrently controlled cohort study, limited and extensive cancer screening strategies were compared. All 630 patients underwent baseline screening consisting of history, physical examination, basic laboratory tests and chest X-ray. In the extensive screening group abdominal and chest CT scan and mammography were added. Outcomes were incidence and curability of cancer, and cancer-related and overall mortality. RESULTS: In 12 of the 342 (3.5%) patients in the extensive screening group malignancy was diagnosed at baseline compared with 2.4% (seven of 288 patients) in the limited screening group. Extensive screening detected six additional cancers (2.0%; 95% CI, 0.74-4.3), of which three were potentially curable. During a median 2.5 years of follow-up, cancer was diagnosed in 3.7% and 5.0% in the extensive and limited screening groups, respectively. In the extensive screening group 26 patients (7.6%) died compared with 24 (8.3%) in the limited screening group; adjusted hazard ratio 1.22 (95% CI, 0.69-2.22). Of these deaths 17 (5.0%) in the extensive screening group and 8 (2.8%) in the limited screening group were cancer related; adjusted hazard ratio 1.79 (95% CI, 0.74-4.35). CONCLUSIONS: The low yield of extensive screening and lack of survival benefit do not support routine screening for cancer with abdominal and chest CT scan and mammography in patients with a first episode of IVTE.


Subject(s)
Mass Screening , Neoplasms/diagnosis , Venous Thromboembolism/etiology , Aged , Chi-Square Distribution , Female , Hospitals, Teaching , Humans , Kaplan-Meier Estimate , Male , Mammography , Mass Screening/methods , Middle Aged , Neoplasms/blood , Neoplasms/complications , Neoplasms/mortality , Netherlands , Predictive Value of Tests , Prognosis , Proportional Hazards Models , Prospective Studies , Risk Assessment , Risk Factors , Time Factors , Tomography, X-Ray Computed , Venous Thromboembolism/blood , Venous Thromboembolism/diagnosis , Venous Thromboembolism/mortality
7.
Support Care Cancer ; 18(8): 1039-60, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20237805

ABSTRACT

PURPOSE: This systematic review aimed to assess the literature for prevalence, severity, and impact on quality of life of salivary gland hypofunction and xerostomia induced by cancer therapies. METHODS: The electronic databases of MEDLINE/PubMed and EMBASE were searched for articles published in English since the 1989 NIH Development Consensus Conference on the Oral Complications of Cancer Therapies until 2008 inclusive. Two independent reviewers extracted information regarding study design, study population, interventions, outcome measures, results and conclusions for each article. RESULTS: The inclusion criteria were met by 184 articles covering salivary gland hypofunction and xerostomia induced by conventional, 3D conformal radiotherapy or intensity-modulated radiotherapy in head and neck cancer patients, cancer chemotherapy, total body irradiation/hematopoietic stem cell transplantation, radioactive iodine treatment, and immunotherapy. CONCLUSIONS: Salivary gland hypofunction and xerostomia are induced by radiotherapy in the head and neck region depending on the cumulative radiation dose to the gland tissue. Treatment focus should be on optimized/new approaches to further reduce the dose to the parotids, and particularly submandibular and minor salivary glands, as these glands are major contributors to moistening of oral tissues. Other cancer treatments also induce salivary gland hypofunction, although to a lesser severity, and in the case of chemotherapy and immunotherapy, the adverse effect is temporary. Fields of sparse literature included pediatric cancer populations, cancer chemotherapy, radioactive iodine treatment, total body irradiation/hematopoietic stem cell transplantation, and immunotherapy.


Subject(s)
Neoplasms/therapy , Salivary Gland Diseases/etiology , Xerostomia/etiology , Evidence-Based Emergency Medicine , Humans , Practice Guidelines as Topic , Prevalence , Quality of Life , Salivary Gland Diseases/epidemiology , Salivary Gland Diseases/physiopathology , Severity of Illness Index , Xerostomia/epidemiology , Xerostomia/physiopathology
8.
Support Care Cancer ; 18(8): 1061-79, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20333412

ABSTRACT

PURPOSE: This systematic review aimed to assess the literature for management strategies and economic impact of salivary gland hypofunction and xerostomia induced by cancer therapies and to determine the quality of evidence-based management recommendations. METHODS: The electronic databases of MEDLINE/PubMed and EMBASE were searched for articles published in English since the 1989 NIH Development Consensus Conference on the Oral Complications of Cancer Therapies until 2008 inclusive. For each article, two independent reviewers extracted information regarding study design, study population, interventions, outcome measures, results, and conclusions. RESULTS: Seventy-two interventional studies met the inclusion criteria. In addition, 49 intensity-modulated radiation therapy (IMRT) studies were included as a management strategy aiming for less salivary gland damage. Management guideline recommendations were drawn up for IMRT, amifostine, muscarinic agonist stimulation, oral mucosal lubricants, acupuncture, and submandibular gland transfer. CONCLUSIONS: There is evidence that salivary gland hypofunction and xerostomia induced by cancer therapies can be prevented or symptoms be minimized to some degree, depending on the type of cancer treatment. Management guideline recommendations are provided for IMRT, amifostine, muscarinic agonist stimulation, oral mucosal lubricants, acupuncture, and submandibular gland transfer. Fields of sparse literature identified included effects of gustatory and masticatory stimulation, specific oral mucosal lubricant formulas, submandibular gland transfer, acupuncture, hyperbaric oxygen treatment, management strategies in pediatric cancer populations, and the economic consequences of salivary gland hypofunction and xerostomia.


Subject(s)
Neoplasms/therapy , Salivary Gland Diseases/etiology , Xerostomia/etiology , Humans , Practice Guidelines as Topic , Radiotherapy, Intensity-Modulated/adverse effects , Radiotherapy, Intensity-Modulated/methods , Salivary Gland Diseases/economics , Salivary Gland Diseases/therapy , Xerostomia/economics , Xerostomia/therapy
9.
Phytomedicine ; 17(8-9): 698-701, 2010 Jul.
Article in English | MEDLINE | ID: mdl-19969445

ABSTRACT

The treatment of neurological disorders and neurodegenerative diseases is related to the levels of acetylcholine (ACh) through the inhibition of acetylcholinesterase (AChE). Galanthamine, an important alkaloid isolated from the Amaryllidaceae family, is approved for the pharmacological treatment of Alzheimer's disease (AD) and acts by inhibiting the acetylcholinesterase (AChE) activity. In the present study, Ellman's method was used to verify the inhibition of AChE activity of some isoquinolines alkaloids such as galanthamine, montanine, hippeastrine and pretazettine. At the concentrations 1mM, 500 microm and 100 microm, galanthamine presented an AChE inhibition higher than 90%. Montanine inhibited, in a dose-dependent manner, more than 50% of the enzyme at 1mM concentration. With the concentrations 500 microm and 100 microm, 30-45% of AChE activity inhibition was detected. The alkaloids hippeastrine and pretazettine presented no significant inhibition of the AChE activity. The results demonstrate that montanine significantly inhibits AChE activity at the tested concentrations, suggesting the necessity of further investigations on this alkaloid use in treating neurological disorders.


Subject(s)
Acetylcholinesterase/metabolism , Alkaloids/pharmacology , Cholinesterase Inhibitors/pharmacology , Isoquinolines/pharmacology , Liliaceae/chemistry , Plant Extracts/pharmacology , Dose-Response Relationship, Drug , Plant Extracts/chemistry , Plant Roots
10.
Rev. bras. farmacogn ; 14(1): 7-14, 2004. tab
Article in Portuguese | LILACS | ID: lil-570837

ABSTRACT

Plantas da família Amaryllidaceae são caracterizadas pela presença de alcalóides isoquinolínicos. Desde o primeiro estudo envolvendo alcalóides desta família em 1877, um grande número destas plantas tem sido analisado quimicamente. Estes compostos apresentam uma ampla variedade de atividades biológicas, tais como: antiviral, citotóxica, antitumoral e analgésica. Neste trabalho, foram avaliados o perfil cromatográfico e a potencial atividade antiviral das frações diclorometano A e B, isoladas dos diferentes órgãos vegetais (bulbos, raízes, folhas e flores) de Hippeastrum glaucescens (Martius) Herbert, assim como dos alcalóides licorina, tazetina e pretazetina, previamente isolados desta planta. A extração dos alcalóides de H. glaucescens foi realizada por métodos clássicos, a partir de bulbos, raízes, folhas e flores fornecendo rendimentos totais em alcalóides de 0,53 por cento; 0,81 por cento; 0,29 por cento e 0,12 por cento, respectivamente. Empregando-se cromatografia em camada delgada, verificou-se que os bulbos e as raízes apresentam perfis cromatográficos semelhantes e que os alcalóides licorina, tazetina e pretazetina estão presentes em todas as partes testadas do vegetal. As frações diclorometano A e B, de cada órgão vegetal, e os alcalóides isolados (licorina, tazetina e pretazetina) não inibiram a replicação do herpesvírus simples humano tipo 1 (HSV-1) cepa KOS, quando avaliados através do método de inibição do efeito citopático viral.


Plants of Amaryllidaceae are characterized by isoquinoline alkaloids. Since the first study with Amaryllidaceae alkaloids in 1877, a large number of these plants have been chemically investigated. These compounds have shown a wide range of biological activities such as: antiviral, cytotoxic, antitumoral and analgesic. In this work, the dichloromethane (CH2Cl2) extracts obtained from different parts of the Hippeastrum glaucescens (Martius) Herbert (bulbs, roots, leaves and flowers) and the isolated alkaloids lycorine, tazettine and pretazettine were analyzed by a chromatographic method (TLC) and tested for antiviral activity. The extraction of alkaloids from bulbs, roots, leaves and flowers of H. glaucescens was performed by classic methods and yields 0.53 percent, 0.81 percent, 0.29 percent and 0.12 percent, respectively. Through TLC, bulbs and roots revealed similar chromatographic profiles and lycorine, tazettine and pretazettine were found in all the parts analyzed. The CH2Cl2-A and CH2Cl2-B extracts from each part of the plant and the isolated alkaloids (lycorine, tazettine and pretazettine) did not inhibit the HSV-1 strain KOS replication, when evaluated through the inhibition of cytophatic viral effect.

SELECTION OF CITATIONS
SEARCH DETAIL
...